BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 23820815)

  • 1. Treatment of idiopathic membranous nephropathy.
    Hofstra JM; Fervenza FC; Wetzels JF
    Nat Rev Nephrol; 2013 Aug; 9(8):443-58. PubMed ID: 23820815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
    Maas R; Hofstra JM; Wetzels JF
    Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic membranous nephropathy.
    Waldman M; Austin HA
    J Am Soc Nephrol; 2012 Oct; 23(10):1617-30. PubMed ID: 22859855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest treatment strategies for membranous nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Expert Opin Pharmacother; 2007 Dec; 8(18):3159-71. PubMed ID: 18035960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of current and alternative therapies for idiopathic membranous nephropathy.
    Tran TH; J Hughes G; Greenfeld C; Pham JT
    Pharmacotherapy; 2015 Apr; 35(4):396-411. PubMed ID: 25884528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Membranous nephropathy: Pathophysiology and natural history].
    Seitz-Polski B; Lambeau G; Esnault V
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Membranous glomerulonephritis: better therapy with autoantibody monitoring?].
    Stahl RA; Hoxha E; Helmchen U
    Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1733-7. PubMed ID: 21877306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and clinical significance of glomerular M-type phospholipase A
    Liu H; Luo W; Gong S; Ding X
    Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
    Stai S; Lioulios G; Christodoulou M; Papagianni A; Stangou M
    J Nephrol; 2023 Mar; 36(2):551-561. PubMed ID: 36450999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of primary membranous nephropathy in 2016.
    van de Logt AE; Hofstra JM; Wetzels JF
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
    Rojas-Rivera J; Fervenza FC; Ortiz A
    Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membranous nephropathy.
    Mathieson PW
    Clin Med (Lond); 2012 Oct; 12(5):461-6. PubMed ID: 23101149
    [No Abstract]   [Full Text] [Related]  

  • 18. The evolution of the therapeutic approach to membranous nephropathy.
    Ponticelli C; Patrizia P; Del Vecchio L; Locatelli F
    Nephrol Dial Transplant; 2021 Apr; 36(5):768-773. PubMed ID: 32206786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary membranous nephropathy: where are we now?
    Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
    J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.